Table 5 The NMA presents the impact of each intervention for recurrence-free survival
placebo | 0.90 (0.51,1.58) | 0.93 (0.68,1.27) | 0.93 (0.30,2.91) | 0.79 (0.38,1.64) |
|---|---|---|---|---|
0.89 (0.51,1.58) | sorafenib | NA | NA | NA |
0.93 (0.68,1.27) | 1.04 (0.54,1.99) | IL2 + IFN + 5FU | NA | NA |
0.93 (0.30,2.91) | 1.04 (0.29,3.72) | 1.00 (0.31,3.26) | tegafur + uracil | NA |
0.79 (0.38,1.64) | 0.89 (0.35,2.23) | 0.85 (0.39,1.88) | 0.85 (0.22,3.27) | thalidomide |